Physician profile
Gina E Clark
NPI 1790065399
$712.11
in general payments reported to CMS, 2019-2025
12 companies · $47.06 in 2025
The $47.06 reported for 2025 was less than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $196 · 2021: $164 · 2022: $30.31 · 2023: $69.35 · 2024: $18.67 · 2025: $47.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $135.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $173.34 | 2019-2020 | |
| Glaxosmithkline, LLC. | $153.04 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $137.15 | 2019-2022 | |
| Novo Nordisk INC | $61.39 | 2020-2025 | Ozempic |
| Novavax INC | $60.92 | 2023-2024 | Novavax Covid-19 Vaccine, Adjuvanted |
| Lilly USA, LLC | $31.92 | 2019 | |
| Janssen Pharmaceuticals, INC | $31.72 | 2022-2023 | Xarelto |
| Mylan Specialty L.P. | $20.38 | 2021 | |
| Pfizer INC. | $12.87 | 2020 | |
| Merck Sharp & Dohme LLC | $12.80 | 2023 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Currax Pharmaceuticals LLC | $11.74 | 2020 | |
| Organon LLC | $4.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.